Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 04, 2018 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, May 10, 2018 at 9:00 a.m. ET to discuss financial results for the first quarter of 2018. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 3866939. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.
Contact:
Jennifer LaVin
617-715-6687
[email protected]
